Clinical Trials for Mesothelioma Patients: Pazopanib Patient Characteristics

Read the patient characteristics criteria about a current clinical trial being conducted to study the effects of Pazopanib for patients who have been diagnosed with mesothelioma.

Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Patient Characteristics:

ECOG performance status 0-2

Life expectancy = 12 weeks

ANC =1,500/mm³

Platelet count = 100,000/mm³

WBC = 3,000/mm³

Bilirubin = 1.5 times upper limit of normal (ULN)

AST and ALT = 2.5 times ULN

Alkaline phosphatase = 2.5 times ULN

Creatinine = 1.5 times ULN or creatinine clearance = 50 mL/min

Proteinuria = 1+ on 2 consecutive dipsticks taken = 1 week apart

PT/INR/PTT = 1.2 times ULN

Not pregnant or nursing

Negative pregnancy test

Fertile patients must use effective nonhormonal contraception

No uncontrolled infection

No uncontrolled blood pressure (BP) (defined as systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg in spite of adequate anti-hypertensive therapy)

No condition that impairs ability to swallow and retain study drug tablets including, but not limited to, any of the following: o Gastrointestinal tract disease resulting in an inability to take oral medication o Requirement for IV alimentation o Prior surgical procedures affecting absorption o Active peptic ulcer disease

No other severe underlying disease that, in the judgment of the investigator, would limit study compliance

No other primary malignancy except for carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and definitively treated = 5 years ago with no subsequent evidence of recurrence o Patients with a history of low-grade (Gleason score = 6) localized prostate cancer are eligible even if diagnosed within the past 5 years

No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study

None of the following concurrent severe and/or uncontrolled medical conditions: o Serious or nonhealing wound, ulcer, or bone fracture o Abdominal fistula, diverticulosis, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days o Poorly controlled diabetes o Interstitial pneumonia o Extensive and symptomatic interstitial fibrosis of the lung

No cardiovascular illness or complication, including any of the following: o Any history of cerebrovascular accident within the past 6 months o History of myocardial infarction (prior electrocardiographic evidence of myocardial injury) o History of cardiac arrhythmia (prior electrocardiographic evidence of abnormal heart rhythm) o Admission for unstable angina o Cardiac angioplasty or stenting within the past 12 months o NYHA class III-IV heart failure

Asymptomatic NYHA class II heart failure allowed o QTc prolongation (defined as a QTc interval = 500 msecs) or other significant electrocardiogram abnormalities o Venous thrombosis within the past 12 weeks ? No symptomatic, untreated, or uncontrolled seizure disorder

No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit study compliance

No significant traumatic injury within the past 4 weeks

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney